San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)Wednesday, January 22, 2014 · 3:48 pm |
|
Cadence: Potential Near Term Catalyst for the Stock (CADX, $5.34)Monday, March 11, 2013 · 7:52 am |
|
Cadence Pharmaceuticals: Sentiment is Shifting from Bearish to Bullish (CADX, $4.90)Thursday, December 20, 2012 · 4:20 pm |
|
Confidence for Success of Ofirmev Launch is Bolstered by Very Strong August Results; Buy is Reiterated (CADX; $4.07)Thursday, September 20, 2012 · 10:33 am |
|
Cadence Strengthens on Positive News FlowMonday, August 27, 2012 · 9:02 am |
|
Cadence Pharmaceuticals: Ofirmev Launch Has Gained Traction; Reiterate BuyFriday, August 3, 2012 · 11:18 am |
|
Cadence Pharmaceuticals: Ofirmev Sales are Likely to Surprise on the Upside in the Second Quarter and Fears of Generic Competition are Overblown (CADX; $2.91)Thursday, June 21, 2012 · 10:00 am |
|
Cadence Pharmaceuticals: The Ofirmev Launch Has Gained Traction (CADX, $2.72)Thursday, May 31, 2012 · 11:21 am |
|
Cadence: Product Recall Doesn't Alter Sales Projections (CADX, $4.19)Sunday, April 8, 2012 · 10:54 am |
|
Many Investors Rate Ofirmev Launch a Failure-Not So Fast (CADX, $4.06)Wednesday, January 25, 2012 · 9:22 am |
|
ANDA Filing Aganist Ofirmev Is Not Unduly Concerning (CADX, $9.25)Monday, July 4, 2011 · 10:21 am |
|
1Q, 2011 Overview: Ofirmev is Experiencing Exceptionally Good Formulary Acceptance (CADX, $7.72)Friday, May 13, 2011 · 3:09 pm |
|
Initial Report: Ofirmev Potential is the Basis for a Buy Recommendation (CADX, $7.10)Monday, May 9, 2011 · 3:25 pm |
|
There are 13 reports on file. |